Trius Therapeutics Acquired By Cubist Pharmaceuticals

San Diego-based Trius Therapeutics is in a deal to be acquired for approximately $707M by Cubist Pharmaceuticals, a fellow biopharmaceuticals firm, the companies said Tuesday. According to the two, Cubist will acquired Trius for $13.50 per share in cash, plus earnout which could bring the transaction to $818M. Cubist said the deal would add a late-stage antibiotic candidate, tedizolid phosphate (TR-701), to its portfolio, along with several pre-clinical antibiotic programs. Trius is being advised by Citi and Centerview Partners LLC, along with Cooley LLP. Cubist is being advised by Barclays and Ropes & Gray LLP.